ArticleMalaria journal2013
Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).
Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Declining genetic polymorphism of the C-terminus Merozoite Surface Protein-1 amidst increased Plasmodium knowlesi transmission in Thailand.Malaria journal · 2024Article
- Declining Genetic Polymorphisms of the C-terminus Merozoite Surface Protein-1 Amidst IncreasedbioRxiv : the preprint server for biology · 2024Article
- Plasmodium knowlesi detection methods for human infections-Diagnosis and surveillance.Advances in parasitology · 2021Article
- Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 (MSP-1) among Plasmodium knowlesi samples from Malaysia.Parasites & vectors · 2018Article
- Within-population genetic diversity and population structure of Plasmodium knowlesi merozoite surface protein 1 gene from geographically distinct regions of Malaysia and Thailand.Malaria journal · 2018Article
- Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.PLoS neglected tropical diseases · 2018Article
- IgG subclass co-expression brings harmony to the quartet model of murine IgG function.Immunology and cell biology · 2016Article
- Expression and Evaluation of Recombinant Plasmodium knowlesi Merozoite Surface Protein-3 (MSP-3) for Detection of Human Malaria.PloS one · 2016Article
- Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies.Malaria journal · 2014Article
- Challenges in diagnosis of Plasmodium knowlesi infections.Tropical parasitology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmodium knowlesi is the fifth Plasmodium species that can infect humans. The Plasmodium merozoite surface protein-1(42) (MSP-1(42)) is a potential candidate for malaria vaccine. However, limited studies have focused on P. knowlesi MSP-1(42).
methodsA ~42 kDa recombinant P. knowlesi MSP-1(42) (pkMSP-1(42)) was expressed using an Escherichia coli system. The purified pkMSP-1(42) was evaluated with malaria and non-malaria human patient sera (n = 189) using Western blots and ELISA. The immunogenicity of pkMSP-1(42) was evaluated in mouse model.
resultsThe purified pkMSP-1(42) had a sensitivity of 91.0% for detection of human malaria in both assays. Specificity was 97.5 and 92.6% in Western blots and ELISA, respectively. Levels of cytokine interferon-gamma, interleukin-2, interleukin-4, and interleukin-10 significantly increased in pkMSP-1(42)-immunized mice as compared to the negative control mice. pkMSP-1(42)-raised antibody had high endpoint titres, and the IgG isotype distribution was IgG1 > IgG2b > IgG3 > IgG2a.
conclusionspkMSP-1(42) was highly immunogenic and able to detect human malaria. Hence, pkMSP-1(42) would be a useful candidate for malaria vaccine development and seroprevalence studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.